You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023312027
Dec 2023110012
Jan 202416109
Feb 2024128021
Mar 202414609
Apr 2024288020
May 2024156027
Jun 202470015
Jul 2024172021
Aug 2024112013
Sep 2024108017
Oct 2024160029
Nov 2024200028
Dec 2024152019
Jan 2025183023
Feb 202550019
Mar 2025005
Apr 20250011
May 20250017
Jun 20250011
Total25080353